Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 03 September 2021

Pearce IP BioBlast®: w/e 03 September 2021

26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for the Northern District of California. The written plea agreements disclosed that the...
Pearce IP BioBlast®: w/e 03 September 2021

Pearce IP BioBlast®: w/e 27 August 2021

24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate to severe plaque psoriasis. 25 Aug 21 | Cipla and Kemwell Biopharma announced that they...
Pearce IP BioBlast®: w/e 03 September 2021

Pearce IP BioBlast®: w/e 20 August 2021

17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by Pfizer and Hospira.  The PTAB declined to deny institution in view of the pending litigation in...
Pearce IP BioBlast®: w/e 03 September 2021

Pearce IP BioBlast®: w/e 13 August 2021

05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar trastuzumab) and pertuzumab administered as an admixture in a single infusion bag is consistent with what is known for reference trastuzumab and...
Pearce IP BioBlast®: w/e 03 September 2021

Pearce IP BioBlast®: w/e 06 August 2021

29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as alternatives to Avastin® (bevacizumab) in the absence of supporting studies. 30 Jul 21 | AbbVie...